Cambridge Healthtech Institute’s 9th Annual
Optimizing Protein Expression
( 蛋白质表现和优化 )
Enhancing Expression Systems
Expression of heterologous proteins presents many challenges and understanding expression systems is key. The 9th annual Optimizing Protein Expression conference delves into protein expression by examining and enhancing expression systems, including CHO and other mammalian systems, E. coli, yeast and baculovirus. What is the best expression system for expressing your protein of choice? Ease and cost of scale-up must be considered to ensure successful bottom-line results. Experts will share case studies and disclose data while divulging details of expression systems’ underlying mechanisms. Comparing and contrasting systems will also be featured to increase understanding in the quest for greater productivity.
PROTEIN PRODUCTION STRATEGIES
New Strategies for Productivity in the Development of Innovative Therapeutic Molecules
Nicola Beaucamp, PhD, Head, Process Research, Roche Innovation Center Munich, Pharma Research and Early Development, Roche Diagnostics GmbH
Site-Specific Biotinylation of Secreted Proteins in Mammalian Cells In Vivo -- Made Viable!
Mark Trautwein, PhD, Senior Scientist, Pharmaceuticals R&D, Preclinical Research, Expression Technologies, Bayer AG
Generation of Superior Host Cell Lines for Biomanufacturing
Holger Laux, PhD, Fellow, Cell Line Development, Novartis Institutes for BioMedical Research, Novartis AG
OPTIMIZING CHO-BASED EXPRESSION
Achieving Predictable Recombinant Gene Expression in CHO Cells Using CRISPR-Mediated Genome Engineering
Nuša Pristovšek, PhD, Postdoctoral Researcher, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
Combining Biophysical Analytics with NGS-Based Genetic Characterization and Gene Editing Technologies to Improve mAb Producing CHO Cell Lines
Holger Thie, PhD, Senior Manager, Technology and Innovation, Biologics Development, Boehringer Ingelheim Pharma GmbH & Co. KG
Importance of Appropriately Glycosylated Species, and Modulation Efforts, to Achieve Desired Post-Translational Modification in CHO-Derived Monoclonal Antibodies
Gaurav Chauhan, MS, Associate Principal Scientist, BioProcess Development, Merck & Co., Inc.
Engineering CHO Cell Lines for the Production of Hard-to-Produce Proteins
Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark
New Tools for Screening & Harvesting Solutions for CHO & HEK293 Cells , for both Transient and Stable Cell
Samuel Ellis, Vice President, Thomson Instrument Company
Expression Optimization of Antibody Fab Fragments in Escherichia coli with Non-Native Amino Acid (NNAA) Incorporated
Harun Rashid, PhD, Senior Principal Scientist, Molecular Technology, Ambrx, Inc.
COMPARE / CONTRAST EXPRESSION SYSTEMS
Microbial or Mammalian Cells for Expression of Therapeutic Antibody Fragments: Making the Choice with the End in Mind
Philippe Billiald, PharmD, PhD, Professor, Biochemistry, University Paris-Sud & Acticor Biotech
Presentation to be Announced
Overcoming Limitations of Conventional Tag Systems – Strep-Tactin®XT Applications
Dennis Karthaus, MSc, IBA Lifesciences